Skip Nav Destination
Issues
1 August 2014
-
Cover Image
Cover Image
Upregulation of HER2 is a hallmark of 20% to 30% of invasive breast cancers, rendering this receptor an attractive target for cancer therapy. Based on the FDA-approved antibody pertuzumab, we have created a panel of bispecific FynomAbs that target two epitopes on HER2. Confocal laser scanning microscopy performed with HER2-positive NCI-N87 cells showed that bispecific FynomAb COVA208 was able—in contrast to pertuzumab and trastuzumab—to relocalize to the intracellular area after five hours of incubation, appearing in a punctate pattern typically seen for internalized drugs. For details, see article by Brack and colleagues on page 2030.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Small Molecule Therapeutics
Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
Monica L. Guzman; Neng Yang; Krishan K. Sharma; Marlene Balys; Cheryl A. Corbett; Craig T. Jordan; Michael W. Becker; Ulrich Steidl; Omar Abdel-Wahab; Ross L. Levine; Guido Marcucci; Gail J. Roboz; Duane C. Hassane
Author Choice
A Novel Small-Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor–Initiating Cells and Overcomes Drug Resistance
Fei-Meng Zheng; Zi-Jie Long; Zhi-Jie Hou; Yu Luo; Ling-Zhi Xu; Jiang-Long Xia; Xiao-Ju Lai; Ji-Wei Liu; Xi Wang; Muhammad Kamran; Min Yan; Shu-Juan Shao; Eric W.-F. Lam; Shao-Wu Wang; Gui Lu; Quentin Liu
Large Molecule Therapeutics
Author Choice
A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action
Simon Brack; Isabella Attinger-Toller; Babette Schade; Frédéric Mourlane; Kristina Klupsch; Richard Woods; Helen Hachemi; Ulrike von der Bey; Susann Koenig-Friedrich; Julian Bertschinger; Dragan Grabulovski
Cancer Biology and Signal Transduction
Companion Diagnostics and Cancer Biomarkers
Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Pei-Pei Kung; Ricardo Martinez; Zhou Zhu; Michael Zager; Alessandra Blasina; Isha Rymer; Jill Hallin; Meirong Xu; Christopher Carroll; John Chionis; Peter Wells; Kirk Kozminski; Jeffery Fan; Oivin Guicherit; Buwen Huang; Mei Cui; Chaoting Liu; Zhongdong Huang; Anand Sistla; Jennifer Yang; Brion W. Murray
Models and Technologies
Biochemical Assays for the Discovery of TDP1 Inhibitors
Christophe Marchand; Shar-yin N. Huang; Thomas S. Dexheimer; Wendy A. Lea; Bryan T. Mott; Adel Chergui; Alena Naumova; Andrew G. Stephen; Andrew S. Rosenthal; Ganesha Rai; Junko Murai; Rui Gao; David J. Maloney; Ajit Jadhav; William L. Jorgensen; Anton Simeonov; Yves Pommier
Advertisement